Indication: WM

Waldenström's
Macroglobulinemia (WM)

Previously Treated
Mantle Cell Lymphoma
(MCL)

Marginal Zone Lymphoma
(MZL)
BTK
Inhibition
Study
Design
Efficacy
& Safety
Dosing
Patient
Support
Sample
Program

CONTACT YOUR REGIONAL MANAGER
FOR MORE INFORMATION

For Canadian healthcare professionals.

Please complete the form below if you would like a BeiGene regional manager to contact you regarding your request to receive further information about BRUKINSA.

Your contact information will only be used by a regional manager to respond to your request. It will not be used for any other purposes unless you register for BeiGene updates by checking the box below.

All fields are required unless marked “optional”.

Title

First Name

Last Name

Designation

Organization (optional)

Email Address

Phone Number

Province/Territory

My request is regarding (check all that apply):

Product information about BRUKINSA (zanubrutinib)

Patient and financial support

Product access

Other

By submitting this form, you agree to allow BeiGene and its agents to collect the information provided and to be contacted directly by a BeiGene regional manager. Your information will not be used for any other purpose than for a regional manager to respond to your request.

I would also like to register for BeiGene updates.

By checking the box above, you agree to allow BeiGene and its agents to collect the information provided as well as to be contacted by BeiGene and its agents in the future regarding BeiGene products and related disease education.

BeiGene will only use your information in accordance with its Privacy Policy.

Expand|Collapse

IMPORTANT SAFETY INFORMATION

INDICATIONS AND CLINICAL USE:

BRUKINSA (zanubrutinib) is indicated:

for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

Pediatrics (<18 years of age):
No safety and efficacy data are available; therefore, Health Canada has not authorized an indication for pediatric use.
Geriatrics (>65 years of age):
No clinically relevant differences in safety or efficacy were observed between patients ≥65 years and those younger than 65 years.

CONTRAINDICATIONS:

BRUKINSA is contraindicated in patients who are hypersensitive to zanubrutinib or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.

Most Serious Warnings and Precautions:

Healthcare professional supervision required:
Treatment with BRUKINSA should be initiated and supervised by a Qualified Healthcare Practitioner experienced in the use of anticancer therapies.
Serious hemorrhage:
(see the BRUKINSA Product Monograph, WARNINGS AND PRECAUTIONS, Hemorrhage).

OTHER RELEVANT WARNINGS AND PRECAUTIONS:

Second primary malignancies:
Monitor patients for skin cancer and advise patients to use sun protection.
Atrial fibrillation and flutter:
Monitor for signs and symptoms of atrial fibrillation and atrial flutter and manage as appropriate.
Driving and operating machinery:
Fatigue, dizziness, and asthenia have been reported in some patients taking BRUKINSA and should be considered when assessing a patient’s ability to drive or operate machines.
Cytopenias:
Monitor complete blood counts regularly during treatment.
Infections:
Monitor patients for signs and symptoms of infection and treat appropriately. Consider prophylaxis according to standard of care in patients who are at increased risk for infections.
Tumour lysis syndrome:
Monitor patients closely and treat as appropriate.
Peri-operative considerations:
Consider the benefit-risk of withholding BRUKINSA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.
Fertility:
No data on the effects of BRUKINSA on fertility in humans are available.
Teratogenic risk:
Advise women of the potential hazard to a fetus and to avoid becoming pregnant during treatment and for at least 1 week after the last dose of BRUKINSA. Advise men to avoid fathering a child while receiving BRUKINSA and for at least 3 months following the last dose of BRUKINSA.
Breastfeeding:
Advise lactating women not to breastfeed during treatment with BRUKINSA and for at least two weeks following the last dose.
Interstitial lung disease (ILD):
Monitor patients for signs and symptoms of ILD.
Hemorrhage:
Patients should be monitored for signs of bleeding.

For more information:

Please consult the BRUKINSA Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information, which has not been discussed in this piece. The Product Monograph is also available by calling 1-877-828-5598.